Characterization of Ursodeoxycholic and Norursodeoxycholic Acid as Substrates of the Hepatic Uptake Transporters OATP1B1, OATP1B3, OATP2B1 and NTCP

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 2, 2012, Pages 81-86

  König, Jörg ^a   Klatt, Sabine ^a   Dilger, Karin ^b   Fromm, Martin F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Dr Falk Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; MESSENGER RNA; NORURSODEOXYCHOLIC ACID; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1; SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; BASOLATERAL MEMBRANE; CELL STRAIN HEK293; CELL TRANSPORT; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; LIVER CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

CLONING, MOLECULAR; HEK293 CELLS; HEPATOCYTES; HUMANS; LIVER; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; SYMPORTERS; URSODEOXYCHOLIC ACID;

MUS;

EID: 84863999754     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00865.x     Document Type: Article

References (28)

1. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006;3:318-28.
2. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007;357:1524-9.
3. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78.
4. Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010;139:1481-96.
5. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130:465-81.
6. Denk GU, Maitz S, Wimmer R, Rust C, Invernizzi P, Ferdinandusse S et al. Conjugation is essential for the anticholestatic effect of norUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology 2010;52:1758-68.
7. Fahrmayr C, Fromm MF, König J. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev 2010;42:380-401.
8. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010;62:1-96.
9. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63:157-81.
10. Huang SM, Zhang L, Giacomini KM. The International Transporter Consortium: a collaborative group of scientists from academia, industry, and the FDA. Clin Pharmacol Ther 2010;87:32-6.
11. König J. Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. In: Fromm MF, Kim RB (eds). Handbook of Experimental Pharmacology. Springer-Verlag, Berlin, Heidelberg, 2011;1-28.
12. Trottier J, El Husseini D, Perreault M, Pâquet S, Caron P, Bourassa S et al. The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver. J Biol Chem 2010;285:1113-21.
13. Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation. In: Fromm MF, Kim RB (eds). Handbook of Experimental Pharmacology. Springer-Verlag, Berlin Heidelberg, 2011;205-59.
14. Maeda K, Kambara M, Tian Y, Hofmann AF, Sugiyama Y. Uptake of ursodeoxycholate and its conjugates by human hepatocytes: role of Na(+)-taurocholate cotransporting polypeptide (NTCP), organic anion transporting polypeptide (OATP) 1B1 (OATP-C), and OATP1B3 (OATP8). Mol Pharm 2006;3:70-7.
15. Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grützner U, Hagenbuch B et al. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 1997;113:1295-305.
16. König J, Glaeser H, Keiser M, Mandery K, Klotz U, Fromm MF. Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos 2011;39:1097-102.
17. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007;35:779-86.
18. Cui Y, König J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55:929-37.
19. Cui Y, König J, Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 2001;60:934-43.
20. König J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275:23161-8.
21. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120:525-33.
22. Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch 2004;447:566-70.
23. Beuers U, Hohenester S, de BuyWenniger LJ, Kremer AE, Jansen PL, Elferink RP. The Binary HCO(3)(-) Umbrella: A Unifying Hypothesis on Pathogenetic and Therapeutic Aspects of Fibrosing Cholangiopathies. Hepatology 2010;52:1489-96.
24. Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 2005;42:1391-8.
25. Yamaguchi H, Okada M, Akitaya S, Ohara H, Mikkaichi T, Ishikawa H et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 2006;47:1196-202.
26. Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF et al. Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. Am J Physiol Gastrointest Liver Physiol 2006;290:G550-6.
27. Xiang X, Vakkilainen J, Backman JT, Neuvonen PJ, Niemi M. No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. Eur J Clin Pharmacol 2011;67:1159-67.
28. Xiang X, Han Y, Neuvonen M, Pasanen MK, Kalliokoski A, Backman JT et al. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenet Genomics 2009;19:447-57.